The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

Conclusion: No new safety signal was observed in patients treated with cladribine tablets, although results are limited by a relatively short duration of follow-up.PMID:37675878 | DOI:10.1080/03007995.2023.2256220

Source: Current Medical Research and Opinion - September 7, 2023 Category: Research Authors: Helmut Butzkueven Jan Hillert Merja Soilu-H änninen Tjalf Ziemssen Jens Kuhle Stig Wergeland Melinda Magyari Joseph R Berger Nicholas Moore Aida Aydemir Irene Bezemer Meritxell Sabid ó Source Type: research